Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Orna Therapeutics, founded in 2019 and headquartered in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA (oRNA) therapeutics. This innovative approach aims to revolutionize RNA medicines and transform disease treatment across multiple areas, including cancer, regenerative medicine, and infectious diseases.
Since its inception, Orna Therapeutics has demonstrated significant growth and investor interest. The company has successfully raised $321 million through multiple funding rounds, with its most recent Series B round in August 2022 securing $221 million. This latest funding round valued the company at $1.5 billion, highlighting the potential investors see in Orna's oRNA technology.
Orna Therapeutics' leadership team brings extensive experience from renowned biotech companies, including CRISPR Therapeutics, Intellia Therapeutics, and Translate Bio. This expertise, combined with the company's innovative technology, positions Orna as a notable player in the competitive biotechnology sector.
While there is currently no official information regarding Orna Therapeutics' IPO plans, the company's substantial funding and high valuation suggest it may be well-positioned for future growth. However, it's important to note that many factors can influence a company's decision to go public, including market conditions, regulatory environment, and internal readiness.
Investors interested in the biotechnology sector and potential future opportunities to invest in Orna Therapeutics should continue to monitor the company's progress and any official announcements regarding its plans for going public.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Orna Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative biotechnology space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech sector, like Orna Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge companies in the rapidly evolving field of RNA therapeutics.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
